Canis ISSN: 2398-2942

Digoxin

Introduction

Name

  • Digoxin.

Class of drug

  • Cardiac glycoside.

Description

Chemical name

  • (3-beta,5-beta,12-beta)-3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1 → 4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1 → 4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide.

Molecular formula

  • C41H64O14.

Physical properties

  • Tablets.
  • Solution.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Drugs reducing digoxin absorption from gastrointestinal (GI) tractDrugs affecting digoxin(increase serum level, decrease elimination rate or enhance the toxic effects)Spironolactone
  • Spironalactone Spironolactone may enhance or decrease the toxic effects of digoxin.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Hogan D F & Sisson D D (1999)Therapeutic monitoring of dogs treated with Digoxin.IN:ACVIM Proceedings 1999. Abstract 79.

Other sources of information

  • Based onSmall Animal Formulary.Tennant Bryn (1999) 3rd edn. Cheltenham: BSAVA.

ADDED